Cargando…

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma

BACKGROUND: Metastatic pancreatic ductal adenocarcinoma (mPDAC) bears a dismal prognosis due to the limited activity of systemic chemotherapy. In our platform for precision medicine, we aim to offer molecular-guided treatments to patients without further standard therapy options. METHODS: In this si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taghizadeh, Hossein, Müllauer, Leonhard, Mader, Robert M., Schindl, Martin, Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357054/ https://www.ncbi.nlm.nih.gov/pubmed/32699558 http://dx.doi.org/10.1177/1758835920938611

Ejemplares similares

Applied precision cancer medicine in metastatic biliary tract cancer
por: Taghizadeh, H., et al.
Publicado: (2020)

Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Molecularly guided treatment of metastatic parotid gland carcinoma in adults
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Applied Precision Cancer Medicine in Neuro-Oncology
por: Taghizadeh, H., et al.
Publicado: (2019)

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors
por: Taghizadeh, Hossein, et al.
Publicado: (2022)

Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Recent advances in precision medicine for pancreatic ductal adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
por: Kieler, Markus, et al.
Publicado: (2019)

Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
por: Yu, Yiqi, et al.
Publicado: (2021)

Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
por: Aust, Stefanie, et al.
Publicado: (2020)

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
por: Houg, Demi S., et al.
Publicado: (2018)

Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine
por: Vernuccio, Federica, et al.
Publicado: (2021)

Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
por: Gerber, Michael H., et al.
Publicado: (2018)

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
por: Taieb, Julien, et al.
Publicado: (2023)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
por: Gruber, Elisabeth S., et al.
Publicado: (2019)

The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
por: Gautam, Shailendra K., et al.
Publicado: (2023)

Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
por: Montemagno, Christopher, et al.
Publicado: (2021)

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
por: Kieler, Markus, et al.
Publicado: (2020)

Correction: Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma
por: Teodorczyk, M, et al.
Publicado: (2015)

A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
por: Wang, Yi, et al.
Publicado: (2018)

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019)

Estimating Metastatic Risk of Pancreatic Ductal Adenocarcinoma at Single-Cell Resolution
por: Chen, Sina, et al.
Publicado: (2022)

Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
por: Varzaru, Bianca, et al.
Publicado: (2023)

Pancreatic ductal adenocarcinoma in colonic wall: metastatic disease or cancerized pancreatic ectopic tissue?
por: Gallo, Graziana, et al.
Publicado: (2020)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective
por: Peretti, Umberto, et al.
Publicado: (2017)

Austrian tricentric real-life analysis of molecular profiles of metastatic biliary tract cancer patients
por: Taghizadeh, Hossein, et al.
Publicado: (2023)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma
por: Jian, Ziying, et al.
Publicado: (2018)

Objective and subjective comparison of virtual monoenergetic vs. polychromatic images in patients with pancreatic ductal adenocarcinoma
por: Beer, Lucian, et al.
Publicado: (2019)

THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
por: Gimotty, Phyllis A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0e1s1nelijf94fv4e0imuj66rj